The FDA panel is going to make some sort of a decision this evening. Trading is currently halted.
I'm optimistic, but this could go either way. *IF* the decision is positive, this billion dollar company will have an additional $500 million in annual sales. The reward justifies the risk. I hope you guys have some.
Sarepta's eteplirsen *IS* safe. The only competing product was just shot down because it wasn't. The question is . . . is there enough proof that it works? Given that the victims are children and that there is little else that can be done for them, I think that marginal evidence of efficacy should still result in a favorable decision.
Now I'm waiting. Tick . . . tick . . . tick.